growth%20hormone%20deficiency
GROWTH HORMONE DEFICIENCY
Growth hormone deficiency in adults reflects an absence of two hormones, growth hormone and insulin-like growth factor-1 (IGF-1), affecting the process of glucose-insulin metabolism, lipolysis and bone remodelling.
History may show pituitary adenoma, surgery &/or radiation treatment of pituitary adenomas or cranial radiation for other disorders, deficiency of other pituitary hormones that may occur concurrently with growth hormone deficiency, and previous childhood growth hormone deficiency.
Physical exam reveals reduced lean body mass with increased weight, body fat predominantly in the abdominal region, thin & dry skin, cool peripheries, poor venous access and blunt affect.

Follow Up

Adults

  • Monitor monthly initially for response to treatment & adjust dose accordingly
  • Plasma glucose should be checked initially & every 3 months
  • Once maintenance doses are achieved, measurement of serum fasting blood sugar (FBS), insulin-like growth factor 1 (IGF-1), hemoglobin A1c (HbA1c), waist circumference, body mass index (BMI), serum free T4, & clinical assessment of hypothalamic-pituitary-adrenal axis or by early morning cortisol or cosyntropin stimulation test (in patients not on glucocorticoid replacement), testosterone, & fasting lipid panel should be done every 6-12 months
  • DEXA (Dual Energy X-ray Absorptiometry) scan is recommended prior to & during growth hormone (GH) therapy
    • 1st DEXA scan after initiation of GH replacement should be done at approx 2 years later & repeated at 2-3 year intervals

Children

  • Monitor every 3-6 months for response to treatment & adjust dose accordingly
  • Monitor thyroid function every 6 months
  • Continue GH therapy if there is persistent growth hormone deficiency (GHD) even after adult height is achieved to obtain full skeletal/muscle maturation during the transition period
  • GHD may persist to adult life
    • Retesting may be required esp in idiopathic GHD patients (retest using adult criteria after 1-3 months w/o GH therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
Yesterday
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
Yesterday
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.
Pank Jit Sin, 4 days ago

The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease.